Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 184.87M P/E - EPS this Y 25.10% Ern Qtrly Grth -
Income -42.62M Forward P/E -5.04 EPS next Y 47.40% 50D Avg Chg -9.00%
Sales 81k PEG - EPS past 5Y - 200D Avg Chg -27.00%
Dividend N/A Price/Book 3.15 EPS next 5Y - 52W High Chg -54.00%
Recommedations 2.00 Quick Ratio 8.84 Shares Outstanding 31.15M 52W Low Chg 35.00%
Insider Own 2.04% ROA -30.91% Shares Float 30.37M Beta 0.15
Inst Own 27.42% ROE -87.96% Shares Shorted/Prior 2.27M/2.13M Price 7.00
Gross Margin 100.00% Profit Margin - Avg. Volume 222,606 Target Price 5.80
Oper. Margin -57,665.44% Earnings Date Oct 31 Volume 107,766 Change -1.96%
About Actinium Pharmaceuticals, Inc.

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company's research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.

Actinium Pharmaceuticals, Inc. News
11/18/24 Actinium Pharmaceuticals Highlights Antibody Radiation Conjugate Program Developments and Reports Financial Results for the Third Quarter 2024
11/14/24 Actinium: Q3 Earnings Snapshot
11/04/24 Actinium Pharmaceuticals Appoints Accomplished Biopharma Industry Executive June Almenoff, M.D., Ph.D. to its Board of Directors
10/18/24 All You Need to Know About Actinium (ATNM) Rating Upgrade to Strong Buy
09/23/24 Actinium Pharmaceuticals reports data from Phase III trial of AML treatment
09/20/24 Actinium Pharmaceuticals Announces Publication of Results from the Phase 3 SIERRA Trial of Iomab-B in the Journal of Clinical Oncology
08/05/24 Actinium: Q2 Earnings Snapshot
08/05/24 Sector Update: Health Care Stocks Fall in Afternoon Trading
08/05/24 Actinium Provides Regulatory Update on Planned BLA Filing and Future Plans for Iomab-B in the U.S.
08/01/24 Actinium Expands Patent Coverage Over Iomab-ACT, its Next-Generation Targeted Radiotherapy Conditioning Agent, for Gene Edited Stem Cell-Based Therapies for Non-Malignant Indications
07/25/24 Actinium Announces FDA Clearance of Iomab-ACT Targeted Conditioning IND Application for Sickle Cell Disease Patients Undergoing Bone Marrow Transplant in Collaboration with Columbia University
07/25/24 Actinium Pharmaceuticals to Present at the 3rd Annual Targeted Radiopharmaceuticals Summit US
07/11/24 3 Under-$10 Biotech Stocks That Could Make You Rich
07/02/24 3 Clinical-Stage Biotech Stocks to Buy for Multibagger Returns
06/20/24 Is Actinium Pharmaceuticals (ATNM) Outperforming Other Medical Stocks This Year?
06/18/24 Treatment of Blood Cancers - Biopharma Companies Building out their Pipeline of Solutions
06/17/24 Biopharma Stocks Quest for Solutions for Acute Myeloid Leukemia (AML)
06/17/24 Actinium Presents First Ever Data Demonstrating Actimab-A in Combination with Leading Menin Inhibitors Leads to Anti-Tumor Control and Potent Leukemic Cell Killing in Preclinical Acute Myeloid Leukemia Models at the 2024 EHA Congress
06/14/24 Actinium Highlights Oral Presentation at EHA 2024 Annual Congress Featuring Improved Outcomes in TP53 Positive Patients Receiving Iomab-B in the Phase 3 SIERRA Trial
06/11/24 Actinium Announces Results of Actimab-A + CLAG-M Combination Trial Highlighted in Oral Presentation at the 2024 Society of Nuclear Medicine & Molecular Imaging Annual Meeting
ATNM Chatroom

User Image Karmic Posted - 9 hours ago

$ATNM With all due respect to screwups by SS and team, It is hard not to get upset with FDA. This screenshot is from a Feb 2017 presentation.

User Image resume777 Posted - 10 hours ago

@yelenarn500 $ATNM they’re getting punished because the FDA reneged on their approval position and advised they do a new dosing and phase 3 trial to only compare against generic chemotherapy. For whatever reason, the 2020 draft and 2022 final FDA AML Guidance focused endpoints on Overall Survival and less on things like durable complete remission. No doubt that those with exclusivity drugs like Venetoclax or Aza would protest the Iomab-B results because it could take away market share. It’s also why EU approval is still a risk. This will be better once Immedica files in 2025. Then at least we can recognize the $35M as a full asset rather than a deferred liability on the balance sheet.

User Image Pinto72 Posted - 13 hours ago

$ATNM 5 mOr BiZnUs DaYz πŸš€πŸš€πŸš€πŸš€πŸš€ @Biotrad3r 🀣🀣🀣🀣🀣

User Image yelenarn500 Posted - 13 hours ago

$ATNM this is literally madness, correct me if i'm wrong but the crossover to iomab B arm was to save the lives of these patients right? So Actinium is getting punished for giving this life saving therapy to the control arm participants? Is this correct?

User Image All_just_a_game Posted - 14 hours ago

$ATNM decimal point error. Corrected to $0.50 and that’s being generous.

User Image SageSpirits Posted - 14 hours ago

$ATNM "yawn"...

User Image Biotrad3r Posted - 14 hours ago

$ATNM 5 more business days. Hoping for answers…

User Image Biotrad3r Posted - 14 hours ago

$ATNM This has to be institutions manipulating stock price enough for accumulation because even with a decent amount of volume, price hasnt moved πŸ€”

User Image Pickerbefore Posted - 14 hours ago

$ATNM stock doomed by having a CEO that is a greedy moron. Get rid of him by some means and the stock will rebound. No confidence in him except to stuff his pocket for ruining the stock. While he was CEO down 95% with no plan except for himself and the BOD that pay themselves well without delivering any stockholder value.

User Image Pinto72 Posted - 15 hours ago

$ATNM YEEEEEEEESSSSSS, DOGGIE!!!!!!! DOOOOOOOOOOOOOWN AGAIN!!!!!!!!! HELLOOOOOOOO, AAVIE πŸš€πŸš€πŸš€πŸš€πŸš€πŸš€πŸš€πŸ€£πŸ€£πŸ€£πŸ€£πŸ€£πŸ€£πŸ€£πŸ€£

User Image gooddoggie Posted - 15 hours ago

$ATNM Oh down again? Don’t worry - the sun will come up tomorrow. Breaking News: The sun came up today and emitted an enormous solar flare which will reach earth in 15 minutes and is expected to destroy all life on earth.

User Image Jimmy1940 Posted - 17 hours ago

$ATNM Even Fox News know this stuff is absurd...https://www.foxnews.com/politics/hacker-obtains-house-ethics-testimony-matt-gaetz-trump-makes-calls-ag-nominee

User Image Pinto72 Posted - 17 hours ago

$ATNM iTs DiFfeRnT tHiS tYmE πŸš€πŸš€πŸš€πŸš€πŸš€πŸ€£πŸ€£πŸ€£πŸ€£πŸ€£πŸ€£

User Image johnny4cures Posted - 17 hours ago

$ATNM That MC seems low, risky but the potential the make groundbreaking changes in the treatment of R n R AML, 18 and over. A much larger patient population than 55 and older, previous IND

User Image HiNoobie Posted - 20 hours ago

$ATNM @johnny4cures is also @buynhold1. He's now pumping a $5.00 price target. Look what it pumped before. Shameless.

User Image johnny4cures Posted - 21 hours ago

$ATNM

User Image Pinto72 Posted - 21 hours ago

$ATNM HELLOOOOOOOOOO, RICHIII!!!!!! 🀣🀣🀣🀣🀣🀣🀣🀣 BANKRUPTCY = AS SOONπŸš€πŸš€πŸš€πŸš€πŸš€πŸš€πŸš€

User Image alcacer123 Posted - 21 hours ago

$ATNM Sorry Robert Kennedy Jr.

User Image fede5910 Posted - 21 hours ago

$ATNM They always taught me that he who doesn't cry doesn't breastfeed. We have to go out and publish our thoughts and our way of seeing things. Let's not stand still like seth. Let's make known the injustice that is being committed with Iomab B and let them listen to us. Corrupt FDA officials must be given a first and last name.

User Image alcacer123 Posted - 21 hours ago

$ATNM I'm forced to do this because stupid Seth never does anything

User Image dj22mich Posted - 21 hours ago

$ATNM did someone fat finger something this morning?

User Image alcacer123 Posted - 21 hours ago

$ATNM I just wrote John Kennedy Jr a tweet explaining our Iomab b situation. I invite all honest investors to do the same. Does anyone know the names and surnames of those responsible for the FDA requesting another study, please send them to me so I can write to them.

User Image alcacer123 Posted - 1 day ago

$ATNM Does the FDA have the authority to continue maintaining that Iomab, after many years of very good results, be subjected to a new meaningless study? . This FDA that is accused by the new leadership of being corrupt. What happened to the congressmen with the requests for a review of this very controversial decision. Here someone has to contact the new ones and explain the situation that is repeated in a lot of small Pharmas that are destroyed by the FDA in favor of the big ones. Seth, did you talk to them with the speed that you give yourself benefits? Seth, how strange that this company can't even be sold for 3, 4 or 5 billion.

User Image Thestocktraderhubzee Posted - 1 day ago

WATCHLIST NOV 20 2024 $SYM DA Davidson Maintains Buy on Symbotic, Maintains $47 Price Target $ATNM Stephens & Co. Reiterates Overweight on Actinium Pharma, Maintains $5 Price Target $IMTX B of A Securities Maintains Buy on Immatics, Lowers Price Target to $15 $FUTU Citigroup Downgrades Futu Hldgs to Neutral, Raises Price Target to $95 $AKYA Piper Sandler Reiterates Overweight on Akoya Biosciences, Lowers Price Target to $3

User Image 1Hamfredbuttlington Posted - 1 day ago

$ATNM anyone on here got the proxy vote from Webull yet?

User Image Karmic Posted - 1 day ago

Non $ATNM Post. Too bad Jerry Springer is not with us. He'd have found himself in a swampy cabinet. Entertainment lives on, even if he does not.

User Image johnny4cures Posted - 1 day ago

$ATNM Why not approve, if it's extending OS, and needs just more data? A second p3, 3.1, 3.2, 3.3. Already just give Iomab B an EA!

User Image gooddoggie Posted - 1 day ago

$ATNM My fellow ATNMers, this time will go down in the anals of history as our darkest hour.

User Image gooddoggie Posted - 1 day ago

$ATNM I HAVE A WORM IN MY BRAIN!!!!!!!!!!!!

User Image Pinto72 Posted - 1 day ago

$ATNM ?????🀣🀣🀣🀣🀣🀣

Analyst Ratings
HC Wainwright & Co. Buy Aug 6, 24
Maxim Group Buy Aug 6, 24
HC Wainwright & Co. Buy Jul 26, 24
HC Wainwright & Co. Buy Jun 17, 24
HC Wainwright & Co. Buy May 21, 24
Stephens & Co. Overweight May 14, 24
HC Wainwright & Co. Buy May 2, 24
Cantor Fitzgerald Overweight Apr 30, 24
HC Wainwright & Co. Buy Apr 29, 24